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II. C-Reactive Protein-Mediated Consumption of Complement by
Poly-L-Lysine Polymers and Other Polycations*,$
BY JOAN SIEGEL, ALEXANDER P. OSMAND, MICHAEL F. WILSON, AND
HENRY GEWURZ§
(From the Department ofImmunology, Rush Medical College, and the Department ofMicrobiology,
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The acute phase reactant, C-reactive protein (CRP),' is associated in man and
other species with processes of inflammation and tissue destruction (3-5), and
may increase as much as 1,000-fold inresponse to an inflammatory stimulus (6).
Human CRP consists of 5 or 6 noncovalently bound subunits ofapproximately
21,500-23,500 daltons (7), and has an amino acid composition similar to that of
immunoglobulin (8). It shows calcium-dependentbinding to and/or precipitation
with the pneumococcal C-polysaccharide (CPS) and phosphate monoesters, and
at low ionic strength reacts with the polyanions heparin, dextran sulfate, and
nucleic acids (9-11). CRP shares with antibodies the ability to initiate certain
functions of potential significance to host defense and inflammation, including
precipitation (12), agglutination (13), opsonization (14), capsular swelling (15),
and complement (C) activation (16, 17). Substances which react with CRP to
result in activation of the classical C pathway include CPS, lecithin, sphingo-
myelin, and protamine; this C consumption can be inhibited by phosphorylcho-
line (16, 17). CRP also combines with T lymphocytes and inhibits certain oftheir
functions (18), and inhibits the aggregation of platelets induced by aggregated
human gamma globulin and thrombin (19).
The ability of protamine to initiate C activation in the presence of CRP
suggested that polycations generally might represent an additional reactivity,
and that the interaction ofCRP and polycations with C might represent a major
function ofthis protein. In the present investigation, a variety of synthetic and
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naturally occurring polycations were surveyed for their ability to activate C in
the presence of CRP.
Materials and Methods
Lysine andL-Lysine Polymers.
￿
L-lysine HCl andlysyl-L-lysine HCl were purchased from the
Sigma Chemical Co., St. Louis, Mo. Tetra-L-lysine HCl was purchased from Miles Laboratories,
Inc., Miles Research Div., Kankakee, Ill. Poly-L-lysine HBr (1,700 daltons) was purchased from
ICN Nutritional Biochemicals Div., International Chemical & Nuclear Corp., Cleveland, Ohio.
Poly-L-lysine HBr polymers of 2,000, 4,000, 8,000, 23,000, 30,000, 70,000, 178,000, and 400,000
daltons were purchased from the Sigma Chemical Co.
L-Arginine Polymers.
￿
Poly-L-arginine HCI, 17,000 daltons, and poly-L-arginine sulfate, 65,000
daltons, were purchased from the Sigma Chemical Co. Poly-L-arginine sulfate, 15,000-50,000
daltons, was purchased from Miles Laboratories Inc., Miles Research Div. These polymers were
not readily soluble in aqueoussolutions, and were used as colloidal suspensions after pH adjust-
ment and sonication.
Poly-L-Ornithine .
￿
Polymers ofL-ornithine (5-20,000 and 165,000 daltons) were obtained as the
hydrobromide salts from the Sigma Chemical Co.
Histone.
￿
Lysine-rich histones (type III) containing 22% lysine and 3.4% arginine, and argi-
nine-rich histones (type VIII) containing 9% lysine and 16% arginine, were purchased from the
Sigma Chemical Co.
Lysozyme. Hen egg white lysozyme was purchased from the Sigma Chemical Co. Human
lysozyme was obtained from Laboratory & Educational Supplies, Inc., Los Angeles, Calif.
Protamine.
￿
Protamine sulfate was purchased from Calbiochem, Los Angeles, Calif.
Phosphorylcholine.
￿
Phosphorylcholine waspurchased as the calcium salt from Sigma Chemi-
cal Co.
PolybreneO (Hexadimethrine Bromide).
￿
Polybrene was purchased from Aldrich Chemical Co.,
Milwaukee, Wis.
Leukocyte Cationic Proteins (LCP).
￿
LCP were obtained from lysosomal granules of rabbit
leukocytes (20-22), and suspended in 0.15 M acetate buffer. The protein concentration was
determined by a modification of the assay described by Fields (23) using bovine serum albumin as
a standard. Polyacrylamide gel electrophoresis (24) showed at least seven distinct cationic compo-
nents.
Myelin Basic Proteins (MBP).
￿
Bovine, monkey, guinea pig, and rabbit MBP were prepared
and generously provided by Dr. Marian Kies ofthe National Institutes of Health, Bethesda, Md.
(25).
Human Sera. Serum samples were obtained and prepared from individuals with elevated
levels of CRP as well as from healthy laboratory personnel as described (17).
Buffers.
￿
Gelatin-veronal-buffered saline (GVB'+), 5% dextrose (DSW++), and glucose-GVB++
(GGVB++) with final ionic strengths equivalent to solutions of 0.075 M NaCl and 0.1 M NaCI (2/3
GVB++) were prepared with optimum calcium and magnesium chloride (17, 26, 27). EDTA and
ethylene glycol bis(f3-aminoethyl ether)N-N'-tetraacetic acid (EGTA) were made to 0.01 Min GVB
at a final pH of 7.4 (EDTA-GVB and EGTA-GVB, respectively).
Antisera.
￿
Rabbit antisera against sheep erythrocytes and human CRP were purchased from
Hyland Div., Travenol Laboratories, Inc., Costa Mesa, Calif.
Antrypol (Suramin).
￿
Sodium Suramin U. S. P. was purchased from FBA Pharmaceuticals,
Inc. New York.
CComponents .
￿
Fresh frozen guinea pigserum was obtained from Texas Biological Laborato-
ries, Inc., Fort Worth, Texas. C1 (27), C2 (27), C-EDTA (26), hydrazine-C (28), and hydrazine-
potassium thiocyanate-treated C (29), were prepared from guinea pig serum. C3, C8, and C9 were
purchased from Cordis Laboratories, Miami, Fla.
CellularIntermediates.
￿
Sheep erythrocytes (E), antibody-sensitized erythrocytes (EA), EACf,
EAC14, EAC4, and EAC142 were prepared according to established methods (26, 27, 30) as
previously described (31). EAC1-7 were purchased from Cordis Laboratories. EAC43 (antrypol)
were prepared by a minor modification of the procedure described by Lachmann et al. (29).
Measurement ofCRP.
￿
CRP was measured by radial immunodiffusion as previously described
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Preparation of CRP.
￿
CRP waspurified from ascites or pleural fluids by affinity chromatogra-
phy basedon the calcium-dependent binding of CRP to CPS (18). The procedurefor this purifica-
tion will be published in detail.'
Preparation ofCRP-DefccientAcutePhaseSerum .
￿
Acutephase serum(CRP >- 100Wg/ml) which
showed maximumreactivity with poly-L-lysine(PLL)and protaminewas centrifuged (10,000 g) for
20 minat 4°C, andthelipids were removed. The serum was applied to a CPS-Biogel column' (Bio-
Rad Laboratories, Richmond, Calif.) equilibrated with veronal-buffered saline with optimum
divalent cations (VBS++) and NaN3 (0.002 M) at 4°C. The serum eluate was monitored by A2aoom
and hemolytic C activity, and was frozen immediately and maintained at -70°C until use.
Assay for Hemolytic C and C-Component Activities.
￿
Theeffect of polycations on the hemolytic
C activity ofnormal andacutephase sera was determined by incubation of serum (0.1 ml), buffer
(0.35 ml 2/3 GVB"), and polycation (0.05 ml) for 60 min at 30°C (17). When CRP was added, the
total vol remained 0.5 ml, and thepolycation wasaddedlast. When agents such as phosphorylcho-
line,tetra-L-lysine (TLL), or Polybrene were assayedfrom theirability to inhibit polycation-CRP-
inducedconsumption of C, varyingdosesofthese substances were prereacted with CRP for30 min
at 37°C in atotal vol of0.2 ml; additional buffer, serum, andreactive polycation (e.g., PLL) or CPS
were added in that order to bring the final reaction vol to 0.5 ml, andthe mixture was preincu-
bated for 60 min at 30°C. Residual hemolytic C and C1, C4, and C2 component activities were
determined as previously described (26, 27, 31). Assays for residual hemolytic C3, C5, and C6
activities were performed in tubesaccordingto the methods described by Lachmann et al. (29). C7
was measured by hemolytic radial diffusion also as describedby Lachmann et al. (29). C8 and C9
hemolytic activities were assayed according to Vroon et al. (32).
Results
Effect of PLL Polymers on Hemolytic C Activity in Acute Phase Se-
rum. Polymers of L-lysine were found to initiate C consumption selectively in
acute phase serum. The reactivity varied markedly according to polymer size.
Polymers of 2,000, 4,000, and 8,000 daltons showed maximum reactivity, induc-
ing 40-100% C consumption at concentrations (5-10 Ag/ml preincubation mix-
ture) 10-fold lower than those (50-100 kkg/ml) showing anticomplementary activ-
ity in normal serum (Fig. 1 and Table 1) . Polymers of 1,700, 11,000, and 23,000
daltons showed moderate (15-30%) C-consuming activity, while L-lysine, lysyl-
L-lysine, TLL, and the largest PLL polymers tested (70,000, 178,000, and 400,000
daltons, respectively). had no (<15%) significant C-consuming activity selec-
tively in acute phase serum.
All the polymers larger than the tetramer, independent of the degree of
polymerization, were anticomplementary at concentrations >50 ,u,g/ml in both
normal and acute phase sera. This nonselective anticomplementary effect,
which occurred at concentrations 10- to 20-fold higher than those inducing C
consumption selectively in acute phase sera, may be analogous to the nonspe-
cific "fixation" of C by PLL in the sera of normal and immunized rabbits
reported by Arnon et al. (33), and probably involves direct interaction with
certain C components.
Identification ofPLL-Induced C Consumption in Acute Phase Serum as a
CRP-Mediated Reaction . The consumption of C in acute phase serum initiated
by PLL, like protamine-initiated C consumption, was found to be mediated via
CRP. Absorption of CRP from acute phase serum (250 hg CRP/ml) by passage
through the CPS-Biogel column resulted in loss of ability of PLL (4,000 daltons)
' Osmand, A. P., R. F. Mortensen, J. Siegel andH. Gewurz. Interactions of C-reactive protein
with the complement system. III. Complement-dependent passive hemolysis initiated by CRP.
Manuscript in preparation.712
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to induce C consumption, and the addition of purified CRP (250 /.g/ml) com-
pletely restored this activity (Fig. 2 A) ; PLL also resulted in C depletion in
normal human serum to which purified ascites CRP had been added (Fig. 2 B).
In these normal human serum-CRP reaction systems, the amount of PLL
optimal for peak CRP-mediated C consumption (2.5 pg/ml) consistently was less
than that required for maximal activity in both acute phase and absorbed-
reconstituted acute phase sera (5 .0-10.0 /Ag/ml) . The optimal polycation concen-
tration appeared to be a function ofboth the individual CRP preparation and the
serum in which the activity was assayed. The higher polycation concentration
required for optimal activity in acute phase serum may reflect the presence of
polyanionic substances known to be elevated during the acute phase. The
relationship between polymer size and C-consuming activity observed in acute
phase serum also could be identified in normal human serum to which CRP was
added. Finally, phosphorylcholine inhibited PLL-initiated consumption of C
(Fig. 3) in amounts (e.g., 10-5 M) which had no inhibitory effect on immune
complex- or zymosan-induced consumption of C . The CRP-mediated C consump-
tion initiated by PLL, like CRP-mediated C consumption initiated by CPS (16),
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FIG. 1 .
￿
Effect of representative polymers of L-lysine (PLL) on C activity of normal (<3 Wg
CRP/ml) and acute phase (75 gg CRP/ml) sera. Residual C activity was measured after 60
min preincubation at 30°C. With small amounts of PLL (<50,ug/ml; optimal, 10 wg/ml), C
consumption was seen selectively in acute phase sera, and only with polymers of optimal
(1,700-23,000 daltons) size. Polymers ?1,700 daltonswere anti-C in amounts >50 Wg/ml.TABLE I
Reactivity of Synthetic and Natural Polycations in CRP-Containing Serum Systems*
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* 0.1 ml serum, 0.35 ml buffer (2/3 GVB++), and0.05 ml polycation were preincubated for 60 min
at 37°C, and assayedforresidual totalhemolytic C activity; +++ represents 60-100%; ++, 30-
60%; +, 15-30%; and -, 0-15% complement consumption.
was inhibited by glycerophosphory1choline and acetylcholine with descreasing
efficiency .
C ComponentDepletionProfile during CRP-PLL Interactions .
￿
PLL (2,000 or
4,000 daltons) added to normal human serum-CRP mixtures induced efficient
depletion ofhemolytic C1, C4, and C2 and substantial (50-80%) depletion of C3
and C5 (Fig. 4). C6 activity showed minimal depletion and levels ofC7, C8, and
C9 were unaffected. Similar depletion profiles were found upon interaction of
protamine with CRP.
Polycation Molecular weight
daltons
Concentrations
tested
Pglml
Complement
consumption
Protamine 4,600 1-1,000 +++
L-lysine 172 1-8,000 -
Lysyl-L-lysine 347 1-4,000 -
Tetra-L-lysine 680 1-5,000 -
Poly-L-lysine 1,700 1-250 +
2,000 1-500 +++
4,000 1-500 +++
8,000 1-500 ++
11,000 1-500 +
23,000 1-500 +
70,000 1-500 -
178,000 1-500 -
400,000 1-500 -
Poly-L-ornithine 5,000-20,000 0.5-500
165,000 0.5-500
Poly-L-arginine 17,000 1-200 +
15,000-50,000 1-200 +
65,000 1-200 -
Polybreneg 5,000-10,000 1-1,000 -
Histone (lysine-rich) 21,000-26,000 10-1,000 +++
Histone (arginine-rich) 12,000-16,000 10-2,000 +++
Myelin basic protein (Bovine) 18,400 25-1,500 +++
Leukocyte cationic protein (rabbit) 4,000-8,000 2.5-100 ++
Lysozyme (egg white) 11,000 5-1,000 -
Lysozyme (human) 15,000 5-1,000 -714
￿
CRP-POLYCATION-INDUCED ACTIVATION OF COMPLEMENT
PLL and CRP alone each consumed C4 at the concentrations used, which were
10- to 20-fold lower than the amounts inducing depletion of total C activity.
Higher concentrations of PLL resulted in C1-consuming activity in absence of
depletion of C4 . The basis of the anti-C4 activity of CRP was not clear; it was
dose dependent, occurred also in serum preheated to 56°C for 30 min to inacti-
vate C1, and was not inhibited by phosphorylcholine.
Effect of Other Synthetic Polycations on C Consumption in CRP-Containing
Sera . Synthetic polycations in addition to PLL were tested for C consumption
in both acute phase serum and normal serum to which CRP had been added.
Low mol wt polymers of L-arginine (17,000 and 15,000-50,000 daltons) showed
intermediate (25%) C consumption which was optimal at 5-10 Ag/ml (Table I),
an activity equivalent to L-lysine polymers of that size range. A higher mol wt
polymer Of L-arginine (65,000 daltons), like PLL polymers in this size range,
showed no C-consuming activity (Table I) . Polymers (5,000-20,000 and 165,000
daltons) of L-ornithine, which differs from L-lysine by a single methylene group,
and Polybrene (5,000-10,000 daltons), a synthetic polymer of hexadimethrine
bromide, did not consume C in the presence of CRP (Table I).
Effects of Naturally Occurring Polycations on C Consumption in CRP-Con-
taining Serum.
￿
Several naturally occurring polycations, including histones,
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￿
C consumption by PLL (4,000 daltons) in the presence and absence of CRP (250
hg/ml). (A) Effect of PLL in acutephase serum, acute phase serum absorbed with CPS by
affinity chromatography, andabsorbed acute phase serum to which purified CRPhadbeen
added; (B) PLL-initiated C consumption in normal human serum in the presence and
absence of CRP (250 hg/ml). C consumption was seen only in the presence of CAP in both
normal and acute phase sera.
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N.g/ml POLY-L-LYSINEMBP, and leukocyte cationic proteins, were tested for their ability to consume C
in the presence of CRP (Table I and Fig. 5). The histones showed marked (>80%)
C-consuming activity when CRP was present, but none in its absence; the
concentration of the lysine-rich histone required for 50% consumption was 10-
fold lower than that of the arginine-rich histone (50 as compared to 500 wg/ml) .
MBP derived from the cow, monkey, rabbit, and guinea pig likewise had
pronounced C-consuming activity in the presence of CRP but none in its ab-
sence ; 50% C consumption was observed with approximately 100 gg bovine
MBP/ml, and maximum reactivity of 80% or greater C consumption was ob-
served with concentrations of 500 wg/ml or more. LCP showed dose-dependent C-
J. SIEGEL, A . P. OSMAND, M. F. WILSON, AND H. GEWURZ
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FIG. 3.
￿
Comparison of the inhibition of CPS-CRP- and PLL-CRP-induced C consumption
by TLL, phosphorylcholine, and Polybrene. The relative inhibitory activity ofthese agents
(Polybrene > phosphorylcholine > TLL) was identical in both systems; larger amounts were
required to inhibit C consumption initiated by CPS.
FIG. 4.
￿
Effect of PLL (2,000 daltons; 2.5 Wg/ml) and CRP (250 pg/ml serum) on C com-
ponent hemolytic activities in normal human serum. The interaction of PLL and CRP in-
duced marked depletion of C1-C5, but had little or no effect on C6-C9.716
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consuming activity which was markedly potentiated in the presence of CRP;
maximum C-consuming activity (>90%) in the presence of CRP was observed
with approximately 300 Ag/ml LCP, while only 38% C consumption was ob-
served in its absence. By contrast, lysozymes of both human and egg white
origin showed no C-consuming activity.
The C-depletion profiles resulting from the interaction oflysine-rich histones
and MBP with CRP in normal human serum were essentially identical to that
induced by PLL. The C consumption induced by lysine-rich histones and MBP
was inhibited by phosphorylcholine; less phosphorylcholine was required for
50% inhibition of C consumption by the lysine-rich histones (7.8 x 10-s M) and
MBP (3 x 10' M) than by PLL (2.4 x 10-5 M) or protamine (1.8 x 10-5 M),
indicating that CRPhas a lower affinity for the lysine-richhistones and forMBP
than it has for PLL or protamine.
Effect of Inactive Polycations on CRP-Mediated Consumption ofC.
￿
TLL in
amounts which had no effect on C consumption by immune complexes or
zymosan inhibited CRP-polycation-mediated C consumption. Concentrations of
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FIG. 5. C consumption by naturally occurring polycations in normal serum to which
purified CRP (250 )zg/ml) hadbeen added. (A) Lysine-rich histone, (B) arginine-rich histone,
(C) bovine MBP, and (D) rabbit leukocyte cationic protein. The histones andMBP induced
significant C consumption selectively in thepresence of CRP, which in addition enhanced C
consumption by leukocyte cationic protein.J . SIEGEL, A. P. OSMAND, M . F. WILSON, AND H. GEWURZ
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2.3 x 10-3 and 1.9 x 10-3 M resulted in 50% inhibition of PLL- (Fig. 3) and
protamine-initiated C consumption, respectively; consumption by histones and
MBP was inhibited at concentrations approximately 2- to 4-fold lower. These
results are consistent with the relative affinities ofCRP for the polycations cited
above. The affinity ofCRP for TLL was found to be much lower than its affinity
for phosphorylcholine, as evidenced by the 100-fold greater relative molar con-
centration of TLL required for inhibition of C activation. TLL also inhibited C
depletion initiated by CPS (Fig. 3); the concentration (4 x 10-3 M) required was
approximately twice that required for inhibition of C consumption by PLL.
Twice as much phosphorylcholine also was required to inhibit C consumption
induced by CPS (4.9 x 10-5 M) than that induced by PLL (2.4 x 10-5 M),
indicating that CRP has a greater affinity for CPS than for PLL.
The other polycations which did not induce C consumption in the presence of
CRP, including the higher molecular weight PLL (e.g., 400,000 daltons), Poly-
brene, poly-L-ornithine (5,000-20,000 daltons), and egg white lysozyme also
inhibited C consumption by active polycationsand CPS; Polybrene was approxi-
mately 100-fold more effective than phosphorylcholine in this respect (Fig. 3).
Discussion
CRP recently wasfound to bea potent activator ofthe C system when reacting
with CPS and choline phosphatides (16). While investigating polyanion-polyca-
tion-induced activation ofC, we foundthat protamine also induced activation of
the primary C pathway by interaction with CRP (17). We therefore wondered
whether polycations generally and certain naturally occurring cationic proteins
specifically could represent significant reactivities for CRP, and inthis way lead
to initiation or modulation ofthe inflammatory response.
In the present investigation synthetic and naturally occurring polycations,
including homopolymers ofL-lysine (1,700-23,000 daltons) and arginine (15,000-
50,000 daltons), histones, MBP, and LCP, were found to activate C via CRP.
Smaller or larger polymers of L-lysine were inactive, suggesting an optimal size
range consistent with the known molecular weights of the histones (34), MBP
(35), and LCP (22). The active naturally occurring polycations are rich in lysine
and arginine (17-25%) with varying ratios and distributions ofthese residues;
MBP, which has a random distribution ofbasic residues, showed the weakest
reactivity with CRP. Other polycations of similar mol wt, including poly-L-
ornithine (5,000-20,000 daltons), Polybrene (5,000-10,000 daltons), and hen egg
(14,000 daltons containing 13% lysine and arginine) (36) and human lysozymes
were without activity. Thus, while the structural characteristics required for
polycations to initiate CRP-mediated C activation are not yet clear, they would
seem to include specific basic groups, polycation molecular size, basic residue
distribution, tertiary structure, and/or critical intermolecular configuration.
Each of the polycations tested which failed to activate C in the presence of
CRP was able to inhibit C activation bythe active polycations as well asby CPS.
It would seem that reactivity with CRP is a property ofpolycations generally,
and additional alteration or aggregation of CRP is required for initiation of C
consumption. Since phosphorylcholine also inhibited C consumption by both
polycations and CPS, it appears that these react at an identical or overlapping718
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combining site or sites on CRP. However, it should be noted that to date binding
of polycations to CRP has been inferred only from these indirect studies involv-
ing C interactions.
CRP seems to have a lower affinity for polycations than for CPS since higher
molar concentrations ofboth phosphorylcholine and polycation were required to
inhibit C consumption by CPS than by the active polycations. Nonetheless,
Polybrene was more effective than phosphorylcholine in inhibiting the C-con-
suming reactions of CRP. Polybrene, a heparin inhibitor, is a synthetic, linear
polymeric, quaternary polyamine; its increased capacity for inhibition may be a
reflection of its polymeric nature rather than the activity of its monomeric unit,
which was calculated to be less than that of phosphorylcholine. This interpreta-
tion is supported by the similar efficiency of inhibition of C consumption
observed with the inactive 400,000 dalton polymer of L-lysine. Whatever the
basis, such polycations may serve a physiological or pharmacological role as a
consequence of an ability to modulate reactions of CRP .
Protamine-CRP-mediated C consumption had been reported to involve non-
immune activation of the primary C pathway characterized by marked depletion
of C1, C4, and C2, with minimal effect on C3-9 (17) . However, in the present
studies the interactions of CRP with PLL and other active polycations including
protamine were shown also to deplete hemolytic C3 and C5. Selective depletion
of Cl-C5 was seen also during CPS-CRP interactions,3 supporting earlier obser-
vations of significant C1, C4, and C2 depletion, electrophoretic conversion of C3,
and distinct but lesser consumption of C3-9 by complexes of CRP and CPS (16).
Since recently CRP was found to initiate C-dependent lysis of erythrocytes
passively coated with CPS (37), it seemsto be a potent activator ofthe primary C
pathway which under suitable conditions can initiate expression of the full
biologic potential of the C system. Whether the interaction of CRP with active
polycations results in C activation at the level of Clq as it does in CRP-CPS
interactions (38), and whether other serum factors are required, is not yet clear.
The naturally occurring polycations with capacity to react with CRP are of
interest since these include leukocyte cationic proteins and histones, which are
available and may accumulate at sites of injury and tissue destruction. Perhaps
reactivity with CRP results in activation of C at inflammatory sites, in modula-
tion of the ability of polycations to initiate mast cell (39) and platelet (40)
activation, or in favoring of CRP binding at anionic cell surface sites. The
reactivity of CRP with the MBP raises the question of CRP involvement in the
pathogenesis of allergic encephalomyelitis, in which MBP has been implicated
(41). Further, since the structure of MBP has been extensively defined (35), this
protein and its fragments should facilitate definition ofthe combining site(s) of
CRP; such investigations have been initiated with Dr. Marian Kies of the
National Institutes of Health, Bethesda, Md.
CRP thus provides an additional route to activation of C-dependent host
reactions, supporting the concept that it is a modulator of the inflammatory
process. The capacity of CRP to interact with polycations with and without C
'Johnson, R., J. Siegel, R. F. Mortensen, A. P. Osmand and H. Gewurz. Interactions of C-
reactive protein with the complement system. IV. CPS-initiated consumption of C via CRP and
antibody. Manuscript in preparation.J . SIEGEL, A. P. OSMAND, M. F. WILSON, AND H. GEWURZ
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activation introduces a potential for physiologic or pharmacologic manipulation
of CRP-initiated C-mediated inflammatory reactions. The interactions between
CRP, polycations, and C may be an important component of host responses in
health and disease.
Summary
Cationic homopolymers of poly-L-lysine were found to activate complement
(C) via C-reactive protein (CRP) and deplete C3 and C5 as well as early-acting C
components. Maximum C consumption was obtained with polymers of 2,000-
8,000 daltons; polymers of 1,700, 11,000, and 23,000 daltons were intermediate in
reactivity, while L-lysine, lysyl-L-lysine, tetra-L-lysine, and polymers of 70,000-
400,000 daltons lacked significant C-consuming activity. Naturally occuring
polycations which consumed C in the presence of CRP included myelin basic
proteins, cationic proteins of rabbit leukocytes, and both lysine- and arginine-
rich histones; poly-L-arginine polymers of 17,000 but not 65,000 daltons also were
C-consuming. Polycations without such reactivity included poly-L-ornithine
(5,000 and 165,000 daltons), egg white and human lysozymes, and Polybrene.
The polycations which failed to induce C consumption via CRP, inhibited its
consumption by both active polycations and by C-polysaccharide (CPS) . The
relative inhibitory capacity of phosphorylcholine and polycations in CPS- and
polycations-CRP systems was consistent with the concept that phosphate esters
and polycations react at the same or an overlapping combining site . The ability
ofcertain polycations to activate C via CRP increases the potential for initiation
of host reactions via C. The capacity of other polycations to inhibit C activation
via CRP introduces a potential for physiologic or pharmacologic manipulation.
These considerations would seem to expand the potential role of CRP in the
initiation and modulation of the inflammatory response.
The authors appreciate the technical assistance and interested support of Carolyn Fortman, and
the generous gifts of myelin basic proteins from Dr. Marian Kies.
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